{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:36Z","timestamp":1790982996970,"version":"4.1.0"},"reference-count":22,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Tenofovir disoproxil fumarate (TDF) is a widely prescribed nucleotide reverse transcriptase inhibitor (NtRTI) for HIV-1 infection. Though generally well-tolerated, proximal renal tubulopathy resulting in full-blown Fanconi syndrome remains a rare but severe complication (&lt;0.1%). Case Presentation: We present the case of a 52-year-old female living with HIV-1 (diagnosed in 1999, CDC stage A3) who had been treated with a TDF-based antiretroviral regimen for 12 years. Upon admission, she complained of progressive bone pain and polyuria over the preceding six months. Laboratory investigations revealed profound hypokalemia, severe hypophosphatemia, hypouricemia, elevated alkaline phosphatase (ALP) and a decline in renal function (creatinine 1.3 mg\/dL from a baseline of 0.7 mg\/dL). Arterial blood gas (ABG) analysis showed a normal anion gap hyperchloremic metabolic acidosis alongside respiratory acidosis. Urinalysis demonstrated profound glycosuria in the setting of normal blood glucose levels, coupled with increased 24 h urinary excretion of potassium and phosphorus. A bone scintigraphy demonstrated a \u201csuper scan\u201d pattern of metabolic etiology, establishing secondary osteomalacia driven by renal phosphate wasting. Secondary hyperparathyroidism and severe vitamin D3 deficiency were also recorded. The diagnosis of TDF-induced Fanconi syndrome was established. TDF was discontinued, and her antiretroviral regimen was modified to tenofovir alafenamide fumarate (TAF), emtricitabine (FTC), darunavir, and ritonavir, combined with vitamin D supplementation. Over a 6-month follow-up period, renal function normalized, electrolyte wasting resolved, and metabolic acidosis completely reversed. Conclusions: This case highlights that TDF-induced proximal tubulopathy can manifest even after a decade of uneventful therapy, particularly when co-administered with a boosted protease inhibitor.<\/jats:p>","DOI":"10.3390\/reports9030244","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:08:14Z","timestamp":1785161294000},"page":"244","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Never Too Late: A Case Report of Severe Fanconi Syndrome Developing After More than a Decade of Silent Tenofovir Disoproxil Fumarate Exposure"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-4811","authenticated-orcid":false,"given":"Vasileios","family":"Petrakis","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0674-3787","authenticated-orcid":false,"given":"Dimitrios","family":"Themelidis","sequence":"additional","affiliation":[{"name":"University Laboratory of Microbiology, University General Hospital Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Panopoulou","sequence":"additional","affiliation":[{"name":"University Laboratory of Microbiology, University General Hospital Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelagia","family":"Kriki","sequence":"additional","affiliation":[{"name":"University Department of Nephrology, University General Hospital Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pipitsa N.","family":"Valsamaki","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-2178","authenticated-orcid":false,"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tang, J.W., Olszyna, D.P., Stephenson, I., and Archuleta, S. (2026). HIV-Now Another Long Term Chronic Condition?. Viruses, 18.","DOI":"10.3390\/v18030283"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21556660.2022.2149963","article-title":"Treatment and comorbidity burden among people living with HIV: A review of systematic literature reviews","volume":"12","author":"Taiwo","year":"2022","journal-title":"J. Drug Assess."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13596535211067599","DOI":"10.1177\/13596535211067599","article-title":"The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir","volume":"27","author":"Schinazi","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4997\/jrcpe.2020.316","article-title":"Tenofovir-induced delayed nephro-osteo toxicity","volume":"50","author":"Kumar","year":"2020","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2217\/pgs.09.115","article-title":"Pharmacogenetics of tenofovir treatment","volume":"10","author":"Labarga","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Gallant","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/10600280231206703","article-title":"Fanconi Syndrome in Patients with Human Immunodeficiency Virus Treated with Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review","volume":"58","author":"Joshi","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3000605231195469","DOI":"10.1177\/03000605231195469","article-title":"Fanconi syndrome induced by the long-term use of tenofovir disoproxil fumarate: A case report and literature review","volume":"51","author":"Li","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/idr13020044","article-title":"Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use","volume":"13","author":"Rao","year":"2021","journal-title":"Infect. Dis. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13596535231186727","DOI":"10.1177\/13596535231186727","article-title":"Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report","volume":"28","author":"Zilwa","year":"2023","journal-title":"Antivir. Ther."},{"key":"ref_11","first-page":"357","article-title":"Fanconi syndrome associated with use of tenofovir in HIV-infected patients: A case report and review of the literature","volume":"15","author":"Quimby","year":"2005","journal-title":"AIDS Read."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0000000000000491","article-title":"Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans","volume":"33","author":"Mateza","year":"2023","journal-title":"Pharmacogenet. Genom."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1590\/s1678-9946202264010","article-title":"Tenofovir-induced renal and bone toxicity: Report of two cases and literature review","volume":"64","author":"Fioroti","year":"2022","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_14","first-page":"59","article-title":"Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End","volume":"18","author":"Casado","year":"2016","journal-title":"AIDS Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14740331003627458","article-title":"Renal toxicity associated with tenofovir use","volume":"9","author":"Alvarez","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/QAD.0000000000003209","article-title":"Renal mitochondrial toxicity: Effects of thymidine analogues and tenofovir disoproxil fumarate in African people with HIV","volume":"36","author":"Hunt","year":"2022","journal-title":"AIDS"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity","volume":"10","author":"Woodward","year":"2009","journal-title":"HIV Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nartey, E.T., Tetteh, R.A., Yankey, B.A., Mantel-Teeuwisse, A.K., Leufkens, H.G.M., Dodoo, A.N.O., and Lartey, M. (2019). Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana. BMC Res. Notes, 12.","DOI":"10.1186\/s13104-019-4454-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13596535211067600","DOI":"10.1177\/13596535211067600","article-title":"Tenofovir alafenamide fumarate","volume":"27","author":"Lee","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12981-021-00380-w","article-title":"Tenofovir alafenamide nephrotoxicity: A case report and literature review","volume":"18","author":"Ueaphongsukkit","year":"2021","journal-title":"AIDS Res. Ther."},{"key":"ref_22","first-page":"184","article-title":"Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?","volume":"18","author":"Aloy","year":"2016","journal-title":"AIDS Rev."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/3\/244\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:35:59Z","timestamp":1785162959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/3\/244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["reports9030244"],"URL":"https:\/\/doi.org\/10.3390\/reports9030244","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}